The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention

Tong Wen Sun, Qing Yan Xu, Hai Mu Yao, Xiao Juan Zhang, Qiong Wu, Jin Ying Zhang, Ling Li, Yan Zhou Zhang, Quan Cheng Kan, Fangxia Guan, Le Xin Wang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: This study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods: A total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 (≥1.35 mg/L). Results: After a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001). Conclusion: High plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.

Original languageEnglish (US)
Pages (from-to)456-462
Number of pages7
JournalHeart and Lung: Journal of Acute and Critical Care
Volume41
Issue number5
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Cystatin C
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Incidence
Survival Rate
Heart Failure
Myocardial Infarction
Regression Analysis
Mortality

Keywords

  • Acute coronary syndrome
  • Cystatin C
  • Major adverse cardiac events
  • Percutaneous coronary intervention
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine

Cite this

The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. / Sun, Tong Wen; Xu, Qing Yan; Yao, Hai Mu; Zhang, Xiao Juan; Wu, Qiong; Zhang, Jin Ying; Li, Ling; Zhang, Yan Zhou; Kan, Quan Cheng; Guan, Fangxia; Wang, Le Xin.

In: Heart and Lung: Journal of Acute and Critical Care, Vol. 41, No. 5, 09.2012, p. 456-462.

Research output: Contribution to journalArticle

Sun, TW, Xu, QY, Yao, HM, Zhang, XJ, Wu, Q, Zhang, JY, Li, L, Zhang, YZ, Kan, QC, Guan, F & Wang, LX 2012, 'The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention', Heart and Lung: Journal of Acute and Critical Care, vol. 41, no. 5, pp. 456-462. https://doi.org/10.1016/j.hrtlng.2012.04.007
Sun, Tong Wen ; Xu, Qing Yan ; Yao, Hai Mu ; Zhang, Xiao Juan ; Wu, Qiong ; Zhang, Jin Ying ; Li, Ling ; Zhang, Yan Zhou ; Kan, Quan Cheng ; Guan, Fangxia ; Wang, Le Xin. / The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. In: Heart and Lung: Journal of Acute and Critical Care. 2012 ; Vol. 41, No. 5. pp. 456-462.
@article{bd3d401cd64541a3b5400ae89edbf60b,
title = "The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention",
abstract = "Background: This study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods: A total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 (≥1.35 mg/L). Results: After a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001). Conclusion: High plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.",
keywords = "Acute coronary syndrome, Cystatin C, Major adverse cardiac events, Percutaneous coronary intervention, Prognosis",
author = "Sun, {Tong Wen} and Xu, {Qing Yan} and Yao, {Hai Mu} and Zhang, {Xiao Juan} and Qiong Wu and Zhang, {Jin Ying} and Ling Li and Zhang, {Yan Zhou} and Kan, {Quan Cheng} and Fangxia Guan and Wang, {Le Xin}",
year = "2012",
month = "9",
doi = "10.1016/j.hrtlng.2012.04.007",
language = "English (US)",
volume = "41",
pages = "456--462",
journal = "Heart and Lung: Journal of Acute and Critical Care",
issn = "0147-9563",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention

AU - Sun, Tong Wen

AU - Xu, Qing Yan

AU - Yao, Hai Mu

AU - Zhang, Xiao Juan

AU - Wu, Qiong

AU - Zhang, Jin Ying

AU - Li, Ling

AU - Zhang, Yan Zhou

AU - Kan, Quan Cheng

AU - Guan, Fangxia

AU - Wang, Le Xin

PY - 2012/9

Y1 - 2012/9

N2 - Background: This study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods: A total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 (≥1.35 mg/L). Results: After a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001). Conclusion: High plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.

AB - Background: This study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods: A total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 (≥1.35 mg/L). Results: After a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001). Conclusion: High plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.

KW - Acute coronary syndrome

KW - Cystatin C

KW - Major adverse cardiac events

KW - Percutaneous coronary intervention

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84865599053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865599053&partnerID=8YFLogxK

U2 - 10.1016/j.hrtlng.2012.04.007

DO - 10.1016/j.hrtlng.2012.04.007

M3 - Article

C2 - 22652172

AN - SCOPUS:84865599053

VL - 41

SP - 456

EP - 462

JO - Heart and Lung: Journal of Acute and Critical Care

JF - Heart and Lung: Journal of Acute and Critical Care

SN - 0147-9563

IS - 5

ER -